Phase II Study of Tailored-Dose Docetaxel in Metastatic Breast Cancer
Status: COMPLETED
Study type: INTERVENTIONAL
Conditions: Metastatic Breast Cancer
Interventions: DRUG: Docetaxel|PROCEDURE: Erythromycin Breath Test (ERMBT)
Sponsor: University of Michigan Rogel Cancer Center
Collaborators: Aventis Pharmaceuticals|Rhone-Poulenc Rorer